Clinical Trial Update: Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update reports an early-phase study of a novel Bispecific AbTCR (anti-CD19/CD22) T-cell therapy for relapsed or refractory B-cell lymphomas,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Bispecific AbTCR (Anti-CD19/CD22) T Cells

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING